As previously announced, BioXcel Therapeutics, Inc. (Nasdaq: BTAI),
a biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology, will host a virtual Neuroscience R&D Day
focused on BXCL502 and other neuroscience pipeline candidates. The
event is set for 1:00 to 2:30 p.m. ET today, Tuesday, Dec. 12.
Vimal Mehta, Ph.D., Chief Executive Officer, and Frank Yocca,
Ph.D., Chief Scientific Officer, will be joined by other members of
the Company’s R&D leadership team. In addition, two
neuropsychiatry experts will participate in the discussion: Jeffrey
Cummings, M.D. Sc.D.(HC), Research Professor in the Department of
Brain Health and Director of the Chambers-Grundy Center for
Transformative Neuroscience at the University of Nevada, Las Vegas,
and Sandra Comer, Ph.D., Professor of Neurobiology in the
Department of Psychiatry at Columbia University.
Event AccessTo access the Virtual Neuroscience
R&D Day presentation, please dial 877-407-5795 (domestic) or
201-689-8722 (international). A live webcast and presentation
materials will be available on the Investors section of the
corporate website, bioxceltherapeutics.com, and a webcast
replay will be available through March 12, 2024.
BioXcel Therapeutics may use its website as a distribution
channel of material information about the Company. Financial and
other important information is routinely posted on and accessible
through the Investors sections of its website at
bioxceltherapeutics.com, In addition, you may sign up to
automatically receive email alerts and other information about the
Company by visiting the “Email Alerts” option under the News/Events
section of the Investors & Media website section and submitting
your email address.
About BXCL501 In indications other than
those approved by the U.S. Food and Drug Administration (FDA) as
IGALMI™ (dexmedetomidine) sublingual film, BXCL501 is an
investigational proprietary, orally dissolving film formulation of
dexmedetomidine, a selective alpha-2 adrenergic receptor agonist.
BioXcel Therapeutics believes that BXCL501 potentially targets an
important mediator of agitation, and the Company has observed
anti-agitation results in multiple clinical trials across several
neuropsychiatric disorders. BXCL501 is under investigation by
BioXcel Therapeutics for the acute treatment of agitation
associated with dementia due to probable Alzheimer’s disease and
for the acute treatment of agitation associated with bipolar I or
II disorder or schizophrenia in the at-home setting. The safety and
efficacy of BXCL501 for these investigational uses have not been
established. BXCL501 has been granted Breakthrough Therapy
designation by the FDA for the acute treatment of agitation
associated with dementia and Fast Track designation for the acute
treatment of agitation associated with schizophrenia, bipolar
disorders, and dementia.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a
biopharmaceutical company utilizing artificial intelligence to
develop transformative medicines in neuroscience and
immuno-oncology. The Company’s drug re-innovation approach
leverages existing approved drugs and/or clinically validated
product candidates together with big data and proprietary machine
learning algorithms to identify new therapeutic indications.
For more information, please
visit bioxceltherapeutics.com.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”)
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). All statements contained in this press
release other than statements of historical fact should be
considered forward-looking statements, including, without
limitation, the date, time and content of the Company’s R&D Day
and its proposed development pipelines. When used herein, words
including “anticipate,” “believe,” “can,” “continue,” “could,”
“designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements use these words or
expressions. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon the
Company’s current expectations and various assumptions. The Company
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. The Company may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
important factors, including, without limitation, the important
factors discussed under the caption “Risk Factors” in its Quarterly
Report on Form 10-Q for the quarterly period ended September 30,
2023, as such factors may be updated from time to time in its other
filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
except as required by law, it disclaims any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo Partners David
Schull T: 858-717-2310 David.Schull@russopartnersllc.comScott
Stachowiak T: 646-942-5630 Scott.Stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
*IGALMI is a trademark of BioXcel Therapeutics, Inc. BT
BIOXCEL THERAPEUTICS is a registered trademark of BioXcel
Therapeutics, Inc. All other
trademarks are the properties of their respective
owners. Copyright © 2023, BioXcel
Therapeutics, Inc. All rights reserved.
BioXcel Therapeutics (NASDAQ:BTAI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
BioXcel Therapeutics (NASDAQ:BTAI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024